English
Антибактериальная терапия обострений ХОБЛ: назначать нельзя не назначать
Л.И. Дворецкий, Е.В. Сергеева
ФГБОУ ВО «Первый Московский государственный медицинский университет им. И.М. Сеченова», кафедра госпитальной терапии №2, г. Москва
Литература
1. Hirschmann J.V. Do acute exacerbations of chronic bronchitis need to be treated with antibiotics No. Current treatment options in infections diseases. 2002;4:381. 2. Boersma G.W. Antibiotics in acute exacerbatios of COPD: the good, the bad and the ugly. Eur. Resp. J. 2012;40:1–3. 3. Nissly T., Prasad S., Stevermer J., Stevermer James. PURLs: Should you consider antibiotics for exacerbations of mild COPD? J. Fam Pract. 2014;63(4):E11–E13. 4. Saint S., Bent S., Vittinghof E., Grady D. Antibiotics in chronic obstructive pulmonary disease exacerbations. A meta-analisis. JAMA. 1995;273;957–60. 5. Ram F.S., Rodriguez-Roisin R., Granados-Navarrete A., Barnes N.C. Antibiotics for exacerbations of chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2006;(2):CD004403. 6. Puhan M., Vollenweider D., Latshang T. et al. Exacerbations of chronic obstructive pulmonary disease: when are antibiotics indicated? A systematic review. Respir. Res. 2007;8:30. 7. Daniels J.M., Snijders D., de Graaff C.S., Vlaspolder F., Jansen H.M., Boersma W.G. Antibiotics in addition to systemic corticosteroids for acute exacerbations of chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 2010;181(2):150–7. 8. Cosio B.G, Garcia-Nunez M., Monso E. et al. Microbiology of COPD exacerbations at hospital admission: the ECOS study. Eur. Resp. J. 2010;36 (Suppl. 54):684s. 9. Mallia P., Message S., Contoli M. et al. Rhinovirus infection induces increases in CD3+ and CD8+ T cells in BAL in COPD patients. Eur. Respir. J. 2010;36 (Suppl. 54):686s. 10. Perotin J.M, Andreoletti L., Deslee G. et al. RT-PCR microarray detection of viral respiratory pathogens demonstrateds the major role of human metapneumovirus and human rhinovirus in acute exacerbations of COPD in France. Eur. Respir. J. 2010;36 (Suppl. 54):686s. 11. Seth S., File T. M. Managing patients with recurrent acute exacerbations of chronic bronchitis: a common clinical problem. Curr. Med. Res. Opin. 2004;20(10):1511–21. 12. Anthonisen N.R., Manfreda J., Warren C.P., Hershfield E.S., Harding G.K., Nelson N.A. Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease. Ann. Intern. Med. 1987;106:196–204. 13. Stockley R.A., O’Brien C., Pye A., Hill S.L. Relationship of sputum color to nature and outpatient management of acute exacerbations of COPD. Chest. 2000;117(6):1638–45. 14. Johnson A.L., Hampson D.F., Hampson N.B. Sputum color: potential implications for clinical practice. Respir. Care. 2008;53(4):450–4. 15. Daniels J.M., de Graaff C.S., Vlaspolder F., Snijders D., Jansen H.M., Boersma W.G. Sputum color reported by patients is not a reliable marker of the presence of bacteria in acute exacerbations of chronic obstructive pulmonary disease. Clin. Microbiol. Infect. 2010;16(6):583–8. 16. Lacoma A., Prat C., Andreo F., Lores L., Ruiz-Manzano J., Ausina V., Domínguez J. Value of procalcitonin, C-reactive protein, and neopterin in exacerbations of chronic obstructive pulmonary disease. Int. J. Chron. Obstruct. Pulmon. Dis. 2011;6:157–69. 17. Tanrıverdi H., Örnek T., Erboy F., Altınsoy B., Uygur F., Atalay F., Tor M. Comparison of diagnostic values of procalcitonin, C-reactive protein and blood neutrophil/lymphocyte ratio levels in predicting bacterial infection in hospitalized patients with acute exacerbations of COPD. Wien Klin. Wochenschr. 2015;127(19–20):756–63. 18. Chang C.H., Tsao K.C., Hu H.C., Huang C.C., Kao K.C., Chen N.H., Yang C.T., Tsai Y.H., Hsieh M.J. Procalcitonin and C-reactive protein cannot differentiate bacterial or viral infection in COP D exacerbation requiring emergency department visits. Int. J. Chron. Obstruct. Pulmon. Dis. 2015;10:767–74. 19. Jacobs M.R. How can we predict bacterial eradication? Intern. J. Inf. Dis. 2003;7 (Suppl. 1):S13–20. 20. Pettigrew M.M., Tsuji B.T., Gent J.F., Kong Y., Holden P.N., Sethi S., Murphy T.F. Effect of fluoroquinolones and macrolides on eradication and resistance of Haemophilus influenzae in chronic obstructive pulmonary disease. Antimicrob. Agents Chemother. 2016;60(7):4151–8. 21. Волков И.К., Катосова Л.К., Щербакова Т.Ш., Клюкина Д.З. Morazella catarrhalis при хронических и рецидивирующих инфекциях дыхательных путей у детей. Антибиотики и химиотерапия. 2012;49:43–7. 22. Стратегия и тактика рационального применения антимикробных средств в амбулаторной практике. Евразийские клинические рекомендации. Москва, 2016. 23. Biedenbach D.J., Badal R.E., Huang M.Y., Motyl M., Singhal P.K., Kozlov R.S., Roman A.D., Marcella S. In vitro activity of oral antimicrobial agents against pathogens associated with community-acquired upper respiratory tract and urinary tract infections: a five country surveillance study. Infect. Dis. Ther. 2016;5(2):139–53. 24. Chodosh S. Clinical significance of the infection-free interval in the management of acute bacterial exacerbations of chronic bronchitis. Chest. 2005;127:2231–6. 25. Llor C., Moragas A., Hernández S., Bayona C., Miravitlles M. Efficacy of antibiotic therapy for acute exacerbations of mild to moderate chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 2012;186(8):716–23. 26. Miravitlles M., Hernández S. Is it possible to identify exacerbations of mild to moderate COPD that do not require antibiotic treatment? CHEST 2013;144(5):1571–7. 27. Lorenz J., Steinfeld P., Drath L., HYPERLINK «https://www.ncbi.nlm.nih.gov/pubmed/?term=Keienburg%20T%5BAuthor%5D&cauthor=true&cauthor_uid=18370461» Keienburg T., HYPERLINK «https://www.ncbi.nlm.nih.gov/pubmed/?term=Troester%20K%5BAuthor%5D&cauthor=true&cauthor_uid=18370461» Troester K. Efficacy and tolerability of 5- vs 10-day cefixime therapy in acute exacerbation of chronic bronchitis. Clin. Drug. Invest. 1998;15:13–20. 28. Arthur M., McAdoo M., Guerra J., HYPERLINK «https://www.ncbi.nlm.nih.gov/pubmed/?term=Maloney%20R%5BAuthor%5D&cauthor=true&cauthor_uid=11862302» Maloney R., HYPERLINK «https://www.ncbi.nlm.nih.gov/pubmed/?term=McCluskey%20D%5BAuthor%5D&cauthor=true&cauthor_uid=11862302» McCluskey D., HYPERLINK «https://www.ncbi.nlm.nih.gov/pubmed/?term=Giguere%20G%5BAuthor%5D&cauthor=true&cauthor_uid=11862302» Giguere G., HYPERLINK «https://www.ncbi.nlm.nih.gov/pubmed/?term=Gomez%20G%5BAuthor%5D&cauthor=true&cauthor_uid=11862302» Gomez G., HYPERLINK «https://www.ncbi.nlm.nih.gov/pubmed/?term=Collins%20JJ%5BAuthor%5D&cauthor=true&cauthor_uid=11862302» Collins J.J. Clinical comparison of cefuroxime axetil with cefixime in the treatment of acute bronchitis. Am. J. Ther. 1996;3:622–9. 29. Lieberman D., Schlaeffer F. Once-a-day cefixime versus co-amoxiclav three times daily in the treatment of lower respiratory infections. J. Antimicrob. Chemother. 1995;35:354–7. 30. Цой А.Н., Гучев И.А., Сафонова Е.В. Цефиксим. Клиническая эффективность при обострении нетяжелой ХОБЛ и влияние на развитие рецидивов заболевания. Лечащий врач. 2011;1:86–90.
Об авторах / Для корреспонденции
Леонид Иванович Дворецкий, д.м.н., профессор, зав. кафедрой госпитальной терапии №2, ФГБОУ ВО «Первый Московский государственный медицинский университет им. И.М. Сеченова». Адрес: 119991,
г. Москва, ул. Б. Пироговская, д. 2. Тел.: (495) 118-83-10. E-mail: dvoretski@mail.ru
Елена Валентиновна Сергеева, к.м.н., доцент кафедры госпитальной терапии №2, ФГБОУ ВО «Первый Московский государственный медицинский университет им. И.М. Сеченова». Адрес: 119991, г. Москва,
ул. Б. Пироговская, д. 2. Тел.: (495) 118-83-10
Похожие статьи
